China Clinical Trial for Therapeutic MR-HIFU Ablation of Uterine Fibroids

This study is currently recruiting participants.
Verified May 2013 by Philips Healthcare
Information provided by (Responsible Party):
Philips Healthcare Identifier:
First received: April 27, 2012
Last updated: May 14, 2013
Last verified: May 2013

The purpose of this study is to demonstrate safety and effectiveness of the Philips Sonalleve Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) for treatment of uterine fibroids in a Chinese population.

Condition Intervention
Uterine Fibroids
Device: MR-HIFU uterine fibroid treatment

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: China Clinical Trial for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids

Further study details as provided by Philips Healthcare:

Primary Outcome Measures:
  • Change in fibroid volume [ Time Frame: At baseline and at 6 months after treatment ] [ Designated as safety issue: No ]
    Proportion of patients with treated fibroid volume at 6 months after treatment reduced to 90% or less of treated fibroid volume at baseline (before MR-HIFU treatment)

  • Adverse Events [ Time Frame: Within 6 months after treatment ] [ Designated as safety issue: Yes ]
    Number of Adverse Events reported as resulting from MR-HIFU treatment

Estimated Enrollment: 100
Study Start Date: May 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MR-HIFU Treatment
Patients in this arm will receive MR-HIFU uterine fibroid treatment
Device: MR-HIFU uterine fibroid treatment
A single treatment session for uterine fibroids with the MR-HIFU device.
Other Name: Philips Sonalleve MR-HIFU

Detailed Description:

This study is to confirm the safety and effectiveness of Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) in ablating uterine tissue associated with symptomatic leiomyomas. The importance of this therapy is that it offers a non-invasive, uterine sparing procedure for the treatment of uterine fibroids in pre- and peri- menopausal women.

MR-HIFU uses ultrasound to heat and thermally ablate fibroid tissue. The MRI system identifies the ultrasound path and monitors heat rise in the fibroid tissue. The goal of the study is to show treatment safety and effectiveness of the Philips Sonalleve MR-HIFU device for uterine fibroids marketing approval in the Chinese market. MR-HIFU will be performed in 100 patients who pass inclusion/exclusion criteria. Safety, quality of life, and imaging endpoints will be evaluated in all study patients at baseline and at 6 months post-treatment. All patients will be followed up for 12 months post-treatment for safety.


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women, age between 18 and 55 years
  • Weight < 140 kg
  • Pre- or peri-menopausal
  • Uterine size < 24 weeks
  • Cervical cell assessment by Pap smear/Thin-prep Cytologic Test (TCT): Normal, Low Grade Squamous Intraepithelial Lesion (SIL), Low risk Human Papillomavirus (HPV) or Atypical Squamous Cells of Uncertain Significance (ASCUS) subtypes of cervical tissue
  • Fibroids selected for treatment meeting the following criteria:

    1. Total planned ablation volume of all fibroids should not exceed 250 ml, and
    2. No more than 5 fibroids should be planned for ablation, and
    3. Dominant fibroid (diameter) is greater than or equal to 3 cm, and
    4. Fibroids which are completely non-enhancing under Magnetic Resonance (MR) contrast agent should not be treated as the identification of treated volume becomes ambiguous
    5. Highly perfused or brighter than myometrium in T2-weighted MRI (according to the T2 contrast obtained using the Philips MR-HIFU protocol) fibroids should not be treated
  • MR-HIFU device accessibility to fibroids such that at least 50% of the total fibroid volume can be treated
  • Willing and able to attend all study visits

Exclusion Criteria:

  • Other pelvic disease (Other mass, endometriosis, ovarian tumor, acute pelvic disease, significant adenomyosis)
  • Desire for future pregnancy
  • Significant systemic disease, even if controlled
  • Positive pregnancy test
  • Hematocrit < 25%
  • Extensive scarring along anterior lower abdominal wall (> 50% of area)
  • Surgical clips in the direct path of the HIFU beam
  • MRI contraindicated
  • MRI contrast agent contraindicated
  • Fibroids not quantifiable on MRI (e.g. multi-fibroid cases where volume measurements are not feasible)
  • Calcifications around or throughout uterine tissues
  • Communication barrier
  • Suspected malignancy
  Contacts and Locations
Please refer to this study by its identifier: NCT01588899

Contact: Bo Song
Contact: Martin Deppe

China, Beijing
Peking University First Hospital Recruiting
Beijing, Beijing, China
Principal Investigator: Qinping Liao         
Sub-Investigator: Xiaoying Wang         
First Affiliated Hospital of Medical College of Xi'an Jiaotong University Recruiting
Xi'an, China
Principal Investigator: Yueling Wang         
Sub-Investigator: Jian Yang         
Sponsors and Collaborators
Philips Healthcare
Principal Investigator: Qinping Liao Peking University First Hospital
Principal Investigator: Yueling Wang First Affiliated Hospital of Medical College of Xi'an Jiaotong University
  More Information

No publications provided

Responsible Party: Philips Healthcare Identifier: NCT01588899     History of Changes
Other Study ID Numbers: 907764
Study First Received: April 27, 2012
Last Updated: May 14, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by Philips Healthcare:
Uterine Leiomyomas
High Intensity Focused Ultrasound

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases processed this record on April 14, 2014